



**VENUS REMEDIES LIMITED**  
**UNAUDITED FINANCIAL RESULTS (PROVISIONAL)**  
**FOR THE QUARTER ENDED 30TH SEPTEMBER, 2016**

( Rs. In Millions)

S. No.	PARTICULARS	Quarter Ended on			Half Year Ended on		Year Ended on
		30/09/2016 Unaudited	30/06/2016 Unaudited	30/09/2015 Unaudited	30/09/2016 Unaudited	30/09/2015 Unaudited	31/03/2016 Audited
<b>1</b>	<b>Net Sales/ Income from operations</b>						
	(a) Net Sales ( Net of Excise Duty )	1060.13	1015.15	1008.66	2075.28	1993.85	3969.84
	(b) Other Operating Income	11.04	16.3	50.78	27.34	54.71	57.11
	<b>Total Income from Operation ( Net )</b>	<b>1,071.17</b>	<b>1,031.45</b>	<b>1,059.44</b>	<b>2,102.62</b>	<b>2,048.56</b>	<b>4,026.95</b>
<b>2</b>	<b>Expenses</b>						
	(a) Consumption of raw materials	670.52	662.17	654.64	1332.69	1244.65	2,419.98
	(b) (Increase)/ Decrease in stock in trade	(0.03)	(18.19)	(7.58)	(18.22)	(2.03)	(21.66)
	(c) Employee benefits expense	62.31	59.43	61.51	121.74	123.33	250.24
	(d) Depreciation & amortisation expense	99.79	98.79	101.06	198.58	200.66	404.68
	(e) Other expenses	145.53	149.10	147.58	294.63	287.38	582.84
	<b>Total expense</b>	<b>978.12</b>	<b>951.30</b>	<b>957.21</b>	<b>1,929.42</b>	<b>1,853.99</b>	<b>3,636.08</b>
<b>3</b>	<b>Profit from operations before other income , finance costs and exceptional items ( 1-2)</b>	<b>93.05</b>	<b>80.15</b>	<b>102.23</b>	<b>173.20</b>	<b>194.57</b>	<b>390.87</b>
	<b>EBIDTA ( 3+2(D)</b>	<b>192.8</b>	<b>178.94</b>	<b>203.3</b>	<b>371.8</b>	<b>395.2</b>	<b>795.55</b>
<b>4</b>	Other income	1.50	1.24	1.19	2.74	2.23	6.65
<b>5</b>	<b>Profit before finance costs and exceptional items ( 3+4)</b>	<b>94.55</b>	<b>81.39</b>	<b>103.42</b>	<b>175.94</b>	<b>196.80</b>	<b>397.52</b>
<b>6</b>	Finance Costs	83.14	69.55	87.37	152.69	178.82	367.40
<b>7</b>	<b>Profit after finance costs but before exceptional items ( 5-6)</b>	<b>11.41</b>	<b>11.84</b>	<b>16.05</b>	<b>23.25</b>	<b>17.98</b>	<b>30.12</b>
<b>8</b>	Exceptional items	-	-	-	-	-	-
<b>9</b>	<b>Profit from ordinary activities before tax ( 7+8)</b>	<b>11.41</b>	<b>11.84</b>	<b>16.05</b>	<b>23.25</b>	<b>17.98</b>	<b>30.12</b>
<b>10</b>	Tax Expenses	-	-	-	-	-	18.08
<b>11</b>	<b>Profit from ordinary activities after tax (9-10 )</b>	<b>11.41</b>	<b>11.84</b>	<b>16.05</b>	<b>23.25</b>	<b>17.98</b>	<b>12.04</b>
<b>12</b>	Exceptional items	-	-	-	-	-	-
<b>13</b>	<b>Net profit for the period ( 11-12)</b>	<b>11.41</b>	<b>11.84</b>	<b>16.05</b>	<b>23.25</b>	<b>17.98</b>	<b>12.04</b>
<b>14</b>	<b>Paid up Equity Share Capital</b>	<b>114.42</b>	<b>114.42</b>	<b>114.42</b>	<b>114.42</b>	<b>114.42</b>	<b>114.42</b>
<b>15</b>	<b>Reserves excluding revaluation reserves</b>	<b>N. A.</b>	<b>N. A.</b>	<b>N. A.</b>	<b>N. A.</b>	<b>N. A.</b>	<b>4,329.87</b>
<b>16</b>	<b>E.P.S - Basic not annualised for the qtr</b>	<b>1.00</b>	<b>1.03</b>	<b>1.40</b>	<b>2.03</b>	<b>1.57</b>	<b>1.05</b>
	- Annualised	<b>3.99</b>	<b>4.14</b>	<b>5.61</b>	<b>4.06</b>	<b>3.14</b>	<b>1.05</b>



## Standalone Statement of Assets and Liabilities

### Venus Remedies Limited

Particulars		Half Year Ended on	Year Ended on
		30/09/2016	31/03/2016
<b>A</b>	<b>EQUITY AND LIABILITIES</b>	(Rs. In Millions)	(Rs. In Millions)
<b>1</b>	<b>Shareholders' funds</b>		
	(a) Share capital	114.42	114.42
	(b) Reserves and surplus	4353.12	4329.87
	<b>Sub-total – Shareholders' funds</b>	4467.54	4444.29
<b>2</b>	<b>Non-current liabilities</b>		
	(a) Long-term borrowings	1814.32	1910.26
	(b) Deferred tax liabilities (net)	165.87	165.86
	(c) Other long-term liabilities	5.91	6.34
	(d) Long-term provisions	34.81	37.88
	<b>Sub-total – Non-current liabilities</b>	2020.91	2120.34
<b>3</b>	<b>Current liabilities</b>		
	(a) Short-term borrowings	1163.64	1150.86
	(b) Trade payables	230.55	239.02
	(c) Other current liabilities	403.95	366.34
	(d) Short-term provisions	5.75	19.68
	<b>Sub-total – Current liabilities</b>	1803.89	1775.9
	<b>TOTAL – EQUITY AND LIABILITIES</b>	8292.34	8340.53
<b>B</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-current assets</b>		
	(a) Fixed assets	5183.94	5138.92
	(b) Non-current investments	287.36	287.36
	(c) Long-term loans and advances	331.16	328.98

<b>Sub-total – Non-current assets</b>	5802.46	5755.26
<b>2 Current assets</b>		
(a) Current investments		
(b) Inventories	1385.7	1376.93
(c) Trade receivables	579.13	538.85
(d) Cash and cash equivalents	29.59	30.44
(e) Short-term loans and advances	495.46	639.05
<b>Sub-total – Current assets</b>	2489.88	2585.27
<b>TOTAL – ASSETS</b>	8292.34	8340.53